4 Evaluating AI-Driven Responses in Breast Reconstruction: A Comparative Study of Response Formats

News
Article
Miami Breast Cancer Conference® Abstracts Supplement42nd Annual Miami Breast Cancer Conference® - Abstracts
Volume 39
Issue 4
Pages: 61

4 Evaluating AI-Driven Responses in Breast Reconstruction: A Comparative Study of Response Formats

4 Evaluating AI-Driven Responses in Breast Reconstruction: A Comparative Study of Response Formats

Background/Significance

Artificial intelligence (AI) is increasingly applied in medicine with significant potential to streamline information retrieval, data processing, and the delivery of comprehensible insights. In breast cancer care, AI’s ability to enhance patient care and improve surgical outcomes is of growing interest. Recently, the accuracy of AI models, such as ChatGPT, in addressing questions about breast reconstruction has garnered interest. While previous studies have examined ChatGPT’s reliability in responding to patient queries, its role as a decision-support tool for surgeons remains largely unexplored.

Materials and Methods

This study evaluated the reliability of recent open AI models, specifically ChatGPT versions 4.0 and 01, in answering standardized in-service plastic surgery exam questions on breast reconstruction. For questions available in both text and image-based formats, ChatGPT 4.0’s accuracy was evaluated with and without images, as it is the only model capable of processing visual inputs. A total of 5 questions were asked, including 1 question available in both text and image-based formats. Responses were assessed against a standardized answer key. Four physicians reviewed the model’s responses across multiple chat sessions, comparing performance on open-ended vs multiple-choice formats.

Results

ChatGPT version 4.0 achieved an average accuracy of 75% in open-ended questions, which increased to 85% in multiple-choice formats. ChatGPT 01, which incorporates reasoning abilities, also scored 75% on open-ended questions but increased to 85% accuracy with multiple-choice. ChatGPT 4.0 demonstrated 100% accuracy on text and image-based open-ended question. However, its performance did not show any significant change with the inclusion of images in the multiple choice format.

Conclusion

The 2 AI models showed distinct strengths depending on the question format—some excelled with structured prompts, while others performed better with open-ended questions with images. AI shows potential as a supplementary tool in breast reconstruction education and decision-making, but its effectiveness is context-dependent. Aligning model strengths with clinical needs is key to maximizing its value alongside expert knowledge.

Articles in this issue

2 Preventive Care and Screening Adherence Among Women Surviving Breast Cancer
2 Preventive Care and Screening Adherence Among Women Surviving Breast Cancer
3 Intraoperative Radiotherapy: Alive and Well in the Bronx
3 Intraoperative Radiotherapy: Alive and Well in the Bronx
4 Evaluating AI-Driven Responses in Breast Reconstruction: A Comparative Study of Response Formats
4 Evaluating AI-Driven Responses in Breast Reconstruction: A Comparative Study of Response Formats
5 Correlation Between Visual Impairment and Breast Cancer: A Cross-Sectional Study Based on the National Health Interview Surveys
5 Correlation Between Visual Impairment and Breast Cancer: A Cross-Sectional Study Based on the National Health Interview Surveys
6 Peer Support Programming Among Women At-Risk for Surviving Breast Cancer: Facilitators and Barriers to Community-Based Patient Navigation and the Role of Quality of Life
6 Peer Support Programming Among Women At-Risk for Surviving Breast Cancer: Facilitators and Barriers to Community-Based Patient Navigation and the Role of Quality of Life
7 Metaplastic Breast Cancer: A Retrospective Chart Review of Clinical Features
7 Metaplastic Breast Cancer: A Retrospective Chart Review of Clinical Features
8 A Case Series Exploring Characteristics and Outcomes of Metachronous Primary Breast and Lung Cancer in a Diverse Cohort
8 A Case Series Exploring Characteristics and Outcomes of Metachronous Primary Breast and Lung Cancer in a Diverse Cohort
9 Body Mass Index, Cancer Risk Behaviors, and Readiness for Dietary Change Among Women Surviving With Breast Cancer
9 Body Mass Index, Cancer Risk Behaviors, and Readiness for Dietary Change Among Women Surviving With Breast Cancer
10 AI as a Bridge: Can ChatGPT Help Patients Understand Their Breast Radiology Reports?
10 AI as a Bridge: Can ChatGPT Help Patients Understand Their Breast Radiology Reports?
12 Gut Microbiome Composition and Pathological Complete Response After Chemotherapy in Breast Cancer: Insights From a Pilot Study
12 Gut Microbiome Composition and Pathological Complete Response After Chemotherapy in Breast Cancer: Insights From a Pilot Study
13 Preliminary Analysis of Change During Treatment of Financial Toxicity and Quality of Life in Breast Cancer Patients
13 Preliminary Analysis of Change During Treatment of Financial Toxicity and Quality of Life in Breast Cancer Patients
15 Utilizing Circulating Tumor Cells to Guide HER2-Directed Therapy in IHC/FISH-Negative HER2+ Metastatic Breast Cancer
15 Utilizing Circulating Tumor Cells to Guide HER2-Directed Therapy in IHC/FISH-Negative HER2+ Metastatic Breast Cancer
16 A Miami Hospital’s Infrastructure to Help Decrease Late-Stage Breast Cancer Diagnosis and Improve Health Equity
16 A Miami Hospital’s Infrastructure to Help Decrease Late-Stage Breast Cancer Diagnosis and Improve Health Equity
17 Salmonella and the Breast: A Literature Review of Salmonella-Induced Breast Abscesses
17 Salmonella and the Breast: A Literature Review of Salmonella-Induced Breast Abscesses
18 Tolerability of First-Line Treatment With Ribociclib for Metastatic Breast Cancer Using 2 Large US Data Sources
18 Tolerability of First-Line Treatment With Ribociclib for Metastatic Breast Cancer Using 2 Large US Data Sources
Recent Videos
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Patients with node-negative disease who are older and have comorbidities may not be suitable to receive CDK4/6 inhibitors.
An observed carryover effect with CDK4/6 inhibitors may reduce the risk of recurrence years after a patient stops treatment.
Breast oncologist Jade E. Jones, MD, says she tries to send patients with BRCA-mutant HR-positive TNBC to clinical trials that use PARP inhibitors.
Related Content